{"product_id":"combining-mri-targeted-and-standard-biopsy-methods-improves-prostate-cancer-diagnosis-what-2-103-men-can-teach-us","title":"Combining MRI-Targeted and Standard Biopsy Methods Improves Prostate Cancer Diagnosis: What 2,103 Men Can Teach Us","description":"One \u003cp\u003e SUMMARY paragraph:\n\nProstate cancer diagnosis is evolving beyond the standard 12-core systematic biopsy, and this landmark study from the National Cancer Institute reveals important insights for patients. Researchers studied 2,103 men with MRI-visible prostate lesions who underwent both MRI-targeted and systematic biopsy during the same procedure, finding that combining the two methods (combined biopsy) detected more cancers overall—including 208 additional cases that either method alone would have missed. While MRI-targeted biopsy alone detected more high-grade (clinically significant) cancers than systematic biopsy, it would still have misclassified 8.8% of dangerous tumors, meaning the combined approach offers the most accurate diagnosis and the fewest instances of under-grading disease before surgery.\n\n\u003cmain\u003e\n\n\u003ch1\u003eCombining MRI-Targeted and Standard Biopsy Methods Improves Prostate Cancer Diagnosis: What 2,103 Men Can Teach Us\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#basics\"\u003eUnderstanding Prostate Biopsy and Cancer Grading\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Study Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: What the Researchers Discovered\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#prostatectomy\"\u003eThe Prostatectomy Sub-Study: Checking the Biopsy's Accuracy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients and Doctors\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a study of 2,103 men with MRI-visible lesions, combined biopsy found more prostate cancers than either MRI-targeted or systematic biopsy alone.\u003c\/li\u003e\n\u003cli\u003eAdding MRI-targeted biopsy to systematic biopsy detected 208 extra cancers, including 59 clinically significant ones (grade group 3 or higher).\u003c\/li\u003e\n\u003cli\u003eMRI-targeted biopsy alone missed 8.8% of clinically significant cancers, so systematic biopsy should not be skipped when lesions are visible.\u003c\/li\u003e\n\u003cli\u003eBefore surgery, combined biopsy reduced upgrading to grade group 3+ to 3.5%, versus 16.8% for systematic biopsy alone.\u003c\/li\u003e\n\u003cli\u003eThe study included only men with MRI-visible lesions; results may not apply to men without such lesions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eProstate cancer is not a single disease. Some prostate cancers grow so slowly that they may never cause harm during a man's lifetime, while others are aggressive and potentially lethal. This dramatic range in behavior—from indolent to deadly—makes accurate diagnosis absolutely critical. Low-grade prostate cancer (grade group 1, also known as Gleason score 3+3=6) has been shown in large clinical trials to carry a very low risk of cancer-specific death. In stark contrast, cancers in grade groups 3 through 5 have significantly higher metastatic potential (the ability to spread to other parts of the body) and are responsible for the majority of the estimated 31,620 deaths from prostate cancer projected in the United States in 2019.\u003c\/p\u003e\n\n\u003cp\u003eThis variation in how lethal different prostate cancers can be highlights a central challenge: how do we accurately determine which men have harmless disease and which have dangerous disease? The answer has profound consequences for treatment decisions.\u003c\/p\u003e\n\n\u003cp\u003eFor decades, the standard method for diagnosing prostate cancer has been the transrectal, ultrasound-guided, 12-core systematic biopsy. In this procedure, a doctor uses ultrasound imaging to guide a needle and takes 12 tissue samples from carefully mapped regions of the prostate. The word \"systematic\" is key—the samples are taken in a grid-like pattern to sample the whole gland, not because the doctor sees a suspicious spot to target.\u003c\/p\u003e\n\n\u003cp\u003eIn most other types of cancer, biopsies target abnormalities that doctors can see on imaging or feel on physical examination. But with systematic prostate biopsy, no such targeting occurs. The biopsy needle samples the prostate somewhat \"blindly,\" relying on spacing rather than vision to find cancer. Not surprisingly, this approach has significant limitations. It can miss cancers that are present, and it can under-gauge the aggressiveness of the cancer that is found.\u003c\/p\u003e\n\n\u003cp\u003eThis diagnostic inaccuracy has serious consequences. Upgrading or downgrading of the cancer diagnosis after radical prostatectomy (complete surgical removal of the prostate) is common. One troubling consequence is overtreatment: men with low-grade, slow-growing disease may undergo aggressive treatment because doctors worry that a dangerous cancer was missed by the biopsy. Research shows that 43% of prostatectomies are performed in men who are subsequently confirmed to have indolent (non-aggressive) disease when the removed prostate is examined under a microscope. Similarly, 60% of men who receive radical therapy (radiation or surgical removal of the prostate) are found to have had grade group 1 cancers on their pre-operative biopsy. On the other end of the spectrum, when aggressive disease is missed, patients risk undertreatment—a potentially deadly mistake.\u003c\/p\u003e\n\n\u003ch2 id=\"basics\"\u003eUnderstanding Prostate Biopsy and Cancer Grading\u003c\/h2\u003e\n\n\u003cp\u003eBefore diving into the study's results, it helps to understand how prostate cancer is graded. When a biopsy sample is examined under a microscope, pathologists assign a \u003cstrong\u003eGleason score\u003c\/strong\u003e ranging from 6 (the lowest grade of cancer) to 10 (the highest grade). The score is the sum of two numbers: the grade of the most common cancer pattern (the first number) and the highest grade pattern detected (the second number).\u003c\/p\u003e\n\n\u003cp\u003eTo make these scores more useful in clinical practice, doctors now group them into \u003cstrong\u003egrade groups\u003c\/strong\u003e from 1 to 5:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade group 1\u003c\/strong\u003e (Gleason score 3+3=6): Clinically insignificant disease with very low risk of spreading\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade group 2\u003c\/strong\u003e (Gleason score 3+4=7): Favorable intermediate risk\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade group 3\u003c\/strong\u003e (Gleason score 4+3=7): Unfavorable intermediate risk and above\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade groups 3 through 5\u003c\/strong\u003e: Considered clinically significant cancers with higher risk of progression\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn this study, researchers defined \"clinically significant cancer\" as grade group 3 or higher, although they also reported detection of grade group 2 or higher throughout the paper, since some physicians consider that lower threshold more clinically relevant.\u003c\/p\u003e\n\n\u003cp\u003eAdvances in prostate \u003cstrong\u003emultiparametric magnetic resonance imaging (MRI)\u003c\/strong\u003e have opened a new frontier in diagnosis. Instead of sampling blindly, doctors can now see suspicious lesions on MRI and guide biopsy needles directly to them—a technique called \u003cstrong\u003eMRI-targeted biopsy\u003c\/strong\u003e. Previous studies have shown that MRI-targeted biopsy detects high-grade cancers at a higher rate than systematic biopsy. However, debate has persisted about whether MRI-targeted biopsy should replace systematic biopsy entirely, or be used alongside it. Two key controversies remained: should doctors still perform the systematic biopsy when an MRI lesion is present, and should a patient's previous biopsy history influence which method is used?\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Study Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eTrio Study\u003c\/strong\u003e was initiated at the National Cancer Institute (NCI) in 2007 and continued through January 2019. It was a substudy of a larger clinical trial called \"Use of Tracking Devices to Locate Abnormalities During Invasive Procedures\" (ClinicalTrials.gov number, NCT00102544). The study was funded by the National Institutes of Health (NIH), among other funders.\u003c\/p\u003e\n\n\u003cp\u003eAdult men aged 18 years or older were eligible if they had an elevated serum \u003cstrong\u003eprostate-specific antigen (PSA)\u003c\/strong\u003e level (a blood test used to screen for prostate cancer) or an abnormal \u003cstrong\u003edigital rectal examination\u003c\/strong\u003e (a physical exam of the prostate). Eligible men underwent prostate MRI, and those found to have a visible lesion who consented to biopsy were enrolled. Exclusion criteria included previous treatment for prostate cancer, no visible MRI lesions, or an inability to undergo MRI (for reasons such as body size incompatible with the MRI equipment, ferrous metallic implants, or claustrophobia). All patients provided written informed consent.\u003c\/p\u003e\n\n\u003cp\u003eA total of 2,732 men underwent prostate MRI during the study period. Of these, 2,180 had MRI-visible lesions and underwent both types of biopsy in the same clinical setting. After excluding 77 men who had undergone previous treatment, the final analysis included \u003cstrong\u003e2,103 men\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eHere is how the biopsy procedures worked:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRI scanning:\u003c\/strong\u003e All initial scans were performed using a 3-tesla MRI (Achieva, Philips) with an endorectal coil (BPX-30, Medrad, Bayer). The endorectal coil was omitted for rare contraindications such as latex allergy, anal fistula, active hemorrhoids, or absence of a rectum. Each MRI was reviewed by one of two expert genitourinary radiologists, each with more than a decade of experience reading prostate MRIs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLesion scoring:\u003c\/strong\u003e MRI lesions were assigned a \u003cstrong\u003eProstate Imaging Reporting and Data System (PI-RADS)\u003c\/strong\u003e score of 1 to 5, with higher scores indicating more clinically suspicious lesions. (Before April 2015, the team used a 5-point NIH-developed scoring system that was subsequently translated to PI-RADS scores.) A maximum of five targets were labeled for biopsy per patient.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRI-targeted biopsy:\u003c\/strong\u003e Using the UroNav Fusion Biopsy System (Philips)—a device developed through a cooperative research-and-development agreement between the NIH and Philips—doctors superimposed the labeled MRI images onto real-time ultrasound scans. This fusion technology allowed them to aim precisely at the MRI-visible lesions. Two biopsy cores were taken from each targeted lesion using an end-fire transrectal ultrasound probe.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSystematic biopsy:\u003c\/strong\u003e After the MRI overlay targets were removed from the ultrasound screen, a second physician performed a standard 12-core extended sextant biopsy using only ultrasound guidance. Systematic cores were taken using standard segmentation to acquire medial and lateral samples from each of the six prostate regions.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eImportantly, the radiologist who interpreted the MRI and assigned targets was never the same person who performed the biopsies. If a doctor noticed targeting information from the MRI-targeted biopsy (such as hemorrhage tracts) during the systematic biopsy, the doctor was instructed to ignore it. Biopsies were performed by urologists, radiologists, or both working together.\u003c\/p\u003e\n\n\u003cp\u003eIf a patient underwent multiple biopsies, only the results of the first combined biopsy were included in the primary biopsy cohort. A single, highly experienced genitourinary pathologist interpreted all biopsy specimens and whole-mount histopathological slides (the full cross-section of the removed prostate gland after surgery), ensuring consistent and expert review. Results were reported following the recommendations of the START (Standards of Reporting for MRI-Targeted Biopsy Studies) Consortium.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: What the Researchers Discovered\u003c\/h2\u003e\n\n\u003cp\u003eOf the 2,103 men included in the analysis, prostate cancer was diagnosed in \u003cstrong\u003e1,312 men (62.4%)\u003c\/strong\u003e by the combined use of both biopsy methods. The majority of participants (79.3%) had undergone at least one biopsy at an outside institution before enrolling in the study, meaning most men were being evaluated either for a suspicious prior finding or to clarify an uncertain previous biopsy result.\u003c\/p\u003e\n\n\u003cp\u003eThe study's primary outcome compared cancer detection rates between MRI-targeted and systematic biopsy, broken down by grade group. The differences were striking:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade group 1 cancers (clinically insignificant):\u003c\/strong\u003e MRI-targeted biopsy detected significantly \u003cem\u003efewer\u003c\/em\u003e of these than systematic biopsy (P\u0026lt;0.001). This is actually good news—it means MRI-targeting was less likely to find harmless cancers that might lead to unnecessary treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade groups 3, 4, and 5 cancers (clinically significant):\u003c\/strong\u003e MRI-targeted biopsy detected significantly \u003cem\u003emore\u003c\/em\u003e of these than systematic biopsy (P=0.004, P\u0026lt;0.001, and P=0.003, respectively). This means MRI-targeting was better at finding the dangerous cancers that matter most.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOverall, systematic biopsy alone detected cancer in 1,104 men (52.5%), while MRI-targeted biopsy alone detected cancer in 1,084 men (51.5%). But the real value of this study lies in what happened when the two methods were combined.\u003c\/p\u003e\n\n\u003ch3\u003eCombined Biopsy: More Cancers Found, More Cancers Correctly Classified\u003c\/h3\u003e\n\n\u003cp\u003eAdding MRI-targeted biopsy to systematic biopsy led to \u003cstrong\u003e208 more cancer diagnoses (9.9%)\u003c\/strong\u003e than either method alone. Of these new diagnoses, 59 (28.4%) were clinically significant cancers (grade group 3 or higher). In other words, nearly one-third of the cancers that would have been missed without MRI-targeting were dangerous ones.\u003c\/p\u003e\n\n\u003cp\u003eThe combined approach also improved the accuracy of cancer grading. Among men whose systematic biopsy found grade group 1 (clinically insignificant) cancer, \u003cstrong\u003e134 men were upgraded to grade group 2 or higher\u003c\/strong\u003e based on MRI-targeted biopsy findings. This upgrading is crucial because it changed their risk category—and likely their treatment plan—from \"watch and wait\" to \"this needs treatment.\" At the same time, MRI-targeted biopsy found \u003cstrong\u003e74 new grade group 1 cancers\u003c\/strong\u003e in men for whom systematic biopsy had found no cancer at all.\u003c\/p\u003e\n\n\u003cp\u003eIn total, MRI-targeted biopsy was responsible for upgrading the cancer classification in \u003cstrong\u003e458 patients (21.8%)\u003c\/strong\u003e when added to systematic biopsy. This means that for more than one in five men, the MRI-targeted approach provided critical additional information that changed their diagnosis to a higher-risk category.\u003c\/p\u003e\n\n\u003cp\u003eHere is a striking finding: the combined biopsy reduced the number of men classified as having clinically insignificant (grade group 1) cancer from 454 to 394—a net reduction of 60 patients. This matters because being incorrectly labeled as having \"harmless\" cancer can lead to under-treatment, while being incorrectly labeled as having \"aggressive\" cancer can lead to unnecessary surgery or radiation.\u003c\/p\u003e\n\n\u003ch3\u003eThe Dangerous Blind Spots of MRI-Targeted Biopsy Alone\u003c\/h3\u003e\n\n\u003cp\u003eSome experts have argued that MRI-targeted biopsy alone could replace systematic biopsy entirely. This study shows why that approach would be risky.\u003c\/p\u003e\n\n\u003cp\u003eMRI-targeted biopsy alone detected clinically significant cancers (grade group 3 or higher) in 425 of 466 patients (91.2%) in whom such cancers were found by combined biopsy. That sounds excellent—but it means \u003cstrong\u003e8.8% of clinically significant cancers would have been missed\u003c\/strong\u003e if only MRI-targeted biopsy had been performed. In absolute numbers, MRI-targeted biopsy alone would have failed to detect:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eCancers of grade group 2 or higher in \u003cstrong\u003e123 patients (5.8%)\u003c\/strong\u003e of the total study population\u003c\/li\u003e\n  \u003cli\u003eCancers of grade group 3 or higher in \u003cstrong\u003e41 patients (1.9%)\u003c\/strong\u003e of the total study population\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePut another way, if doctors had skipped the systematic biopsy, they would have missed the opportunity to reclassify 330 patients (15.7%) into a higher-risk category. These are men who might have been told their cancer was low-risk when it was actually aggressive.\u003c\/p\u003e\n\n\u003cp\u003eInterestingly, the reverse was also true. Of the 466 patients with grade group 3 or higher cancers detected on combined biopsy, 175 (37.6% of those with clinically significant cancer) were detected by MRI-targeted biopsy only, and 41 (8.8%) were detected by systematic biopsy only (P\u0026lt;0.001). Each method caught dangerous cancers that the other one missed—which is precisely why they work better together.\u003c\/p\u003e\n\n\u003ch2 id=\"prostatectomy\"\u003eThe Prostatectomy Sub-Study: Checking the Biopsy's Accuracy\u003c\/h2\u003e\n\n\u003cp\u003eThe ultimate test of a biopsy's accuracy is what happens when the entire prostate is removed and examined. In this study, 404 of the 1,312 men diagnosed with cancer (19.2% of all participants) underwent radical prostatectomy at the NCI. The median time between biopsy and surgery was \u003cstrong\u003e98 days\u003c\/strong\u003e (interquartile range, 74 to 134 days).\u003c\/p\u003e\n\n\u003cp\u003eResearchers compared the grade group determined on biopsy with the grade group determined on whole-mount histopathological analysis—that is, examining the entire prostate gland, sliced and mounted on slides, after surgical removal. This comparison revealed how often the biopsy misclassified the cancer's true aggressiveness.\u003c\/p\u003e\n\n\u003cp\u003eFor the outcome that matters most clinically—upgrading to grade group 3 or higher (meaning the biopsy underestimated the cancer as lower-risk than it actually was)—the combined biopsy approach was clearly superior:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCombined biopsy:\u003c\/strong\u003e Only \u003cstrong\u003e3.5%\u003c\/strong\u003e of men were upgraded to grade group 3 or higher after surgery\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRI-targeted biopsy alone:\u003c\/strong\u003e \u003cstrong\u003e8.7%\u003c\/strong\u003e of men were upgraded to grade group 3 or higher\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSystematic biopsy alone:\u003c\/strong\u003e \u003cstrong\u003e16.8%\u003c\/strong\u003e of men were upgraded to grade group 3 or higher\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis is one of the most powerful findings in the study. When both biopsy methods were used, the risk of under-estimating a cancer's severity was less than one-quarter of the risk with systematic biopsy alone (3.5% vs. 16.8%). For men facing the life-altering decision of whether to have their prostate removed, this accuracy is invaluable.\u003c\/p\u003e\n\n\u003cp\u003eThe patient population in the prostatectomy cohort was typical of men undergoing surgery for prostate cancer: their mean age was 62.0 years, their median PSA was 6.9 ng\/ml, and 45.6% had PI-RADS score 5 lesions (the most suspicious category) on MRI.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis study provides strong evidence that for men with MRI-visible prostate lesions, the most accurate diagnostic approach is \u003cstrong\u003ecombined biopsy\u003c\/strong\u003e—performing both MRI-targeted and systematic biopsy in the same session. The combined approach detected more cancers overall, found more clinically significant cancers, and dramatically reduced the risk that a man would be told his cancer was low-grade when it was actually high-grade.\u003c\/p\u003e\n\n\u003cp\u003eHere's what this means from a patient's perspective:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYou want the most accurate grade possible.\u003c\/strong\u003e The grade group determined on biopsy drives treatment decisions—whether to choose active surveillance, surgery, radiation, or focal therapy. An inaccurate grade can lead to either unnecessary aggressive treatment or dangerous under-treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRI-targeted biopsy alone is not enough.\u003c\/strong\u003e Even though MRI-targeting found more high-grade cancers than systematic biopsy, it still missed 8.8% of clinically significant cancers. Skipping the systematic biopsy would leave these dangerous tumors undiscovered.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe combined biopsy is not just about finding more cancer—it's about finding the right cancer.\u003c\/strong\u003e The combined approach reduced how many men were labeled as having clinically insignificant cancer (grade group 1) from 454 to 394, meaning fewer men were incorrectly placed in the \"low-risk\" category.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrevious biopsy status matters but does not eliminate the benefit of combined biopsy.\u003c\/strong\u003e The majority of men in this study (79.3%) had undergone a prior biopsy before entering the study. The combined approach still found significant additional cancers in these men, showing that even after a previous negative or positive biopsy, both methods together provide the most complete picture.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eEvery study has limitations, and this one is no exception. It is important for patients to understand these caveats so they can interpret the findings appropriately.\u003c\/p\u003e\n\n\u003cp\u003eFirst, this was a single-institution study conducted at the National Cancer Institute, a specialized research center with extraordinary expertise in prostate MRI and biopsy. The radiologists had more than a decade of experience, and a single expert pathologist reviewed every specimen. Results might differ in community hospitals or smaller practices with less specialized experience. The consistency of expert review is both a strength (ensuring accuracy) and a limitation (reducing generalizability).\u003c\/p\u003e\n\n\u003cp\u003eSecond, the study did not compare treatment outcomes. It shows that combined biopsy provides more accurate diagnosis and grading, but it does not prove that this diagnostic accuracy translates into improved survival or quality of life. That would require a much longer randomized trial.\u003c\/p\u003e\n\n\u003cp\u003eThird, the prostatectomy cohort (404 men) represents only a subset of the men diagnosed with cancer, and men who choose surgery may differ from men who choose other treatments. The upgrading data therefore may not apply equally to all patients.\u003c\/p\u003e\n\n\u003cp\u003eFourth, the study focused exclusively on men with MRI-visible lesions. Men with no visible lesions on MRI (552 of the original 2,732 who underwent MRI) were excluded from the analysis, so the findings cannot be generalized to men whose MRIs show no suspicious areas.\u003c\/p\u003e\n\n\u003cp\u003eFinally, some statistical analyses were performed post hoc (after the data had already been examined) during the peer review and revision process, which carries a slightly higher risk of finding patterns that might not be reproducible in a new dataset.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients and Doctors\u003c\/h2\u003e\n\n\u003cp\u003eBased on the study's comprehensive data, the authors conclude that among patients with MRI-visible lesions, combined biopsy led to more detection of all prostate cancers. Notably, MRI-targeted biopsy alone underestimated the histologic grade (aggressiveness) of some tumors, while after radical prostatectomy, upgrades to grade group 3 or higher on histopathological analysis were substantially lower after combined biopsy.\u003c\/p\u003e\n\n\u003cp\u003eFor patients facing a prostate cancer diagnosis, these findings suggest some practical takeaways:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about MRI before your biopsy.\u003c\/strong\u003e If you are undergoing evaluation for suspected prostate cancer, ask whether a multiparametric prostate MRI can be performed to look for visible lesions that can be targeted. The study's patients all had MRI-visible lesions, and the entire benefit of MRI-targeting depends on having something to see.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss whether both biopsy types will be performed together.\u003c\/strong\u003e The study strongly supports performing MRI-targeted and systematic biopsy in the same session (combined biopsy). Each method caught cancers the other missed, and the combined approach dramatically reduced upgrade rates after surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not accept a low-risk diagnosis without confidence.\u003c\/strong\u003e If you are told your cancer is grade group 1 (clinically insignificant), it is worth confirming that the assessment was based on a robust sampling. The study found that systematic biopsy alone misclassified some men as grade group 1 who actually had more aggressive disease. Combined biopsy significantly reduced this risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand that imaging expertise matters.\u003c\/strong\u003e The accuracy of MRI-targeted biopsy depends heavily on the quality of the MRI and the experience of the radiologists and urologists performing the procedure. When discussing biopsy options with your doctor, ask about their experience with MRI-fusion biopsy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeigh the implications for treatment planning.\u003c\/strong\u003e An accurate grade group is the foundation of a sound treatment plan. Whether you're considering active surveillance, surgery, or radiation, insist on the most accurate diagnosis available—which, according to this study, means combined biopsy.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe findings from this study represent a significant step forward in the fight against one of the most common cancers in men. By demonstrating that combining MRI-targeted and systematic biopsy provides the most accurate diagnosis, the researchers have given patients and doctors a clearer path to making informed, life-changing treatment decisions.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is a combined prostate biopsy?\u003c\/h3\u003e\n\u003cp\u003eA combined biopsy uses two methods in one session: an MRI-targeted biopsy, where needles are guided to suspicious spots seen on MRI, and a standard 12-core systematic biopsy, which samples the prostate in a grid pattern. In a study of 2,103 men, combining them found more cancers and gave a more accurate cancer grade than either method alone.\u003c\/p\u003e\n\u003ch3\u003eHow much better is combined biopsy at finding dangerous prostate cancers?\u003c\/h3\u003e\n\u003cp\u003eIn 2,103 men with MRI-visible lesions, adding MRI-targeted biopsy to systematic biopsy led to 208 more cancer diagnoses than either method alone. Of these, 59 (about 28%) were clinically significant cancers (grade group 3 or higher). Combined biopsy also found more high-grade cancers overall than either method alone.\u003c\/p\u003e\n\u003ch3\u003eDoes combining biopsy methods reduce the chance that surgery will reveal a more aggressive cancer?\u003c\/h3\u003e\n\u003cp\u003eYes. Among 404 men who had their prostate removed, upgrading to grade group 3 or higher after surgery occurred in only 3.5% with combined biopsy, compared with 8.7% for MRI-targeted biopsy alone and 16.8% for systematic biopsy alone. That means combined biopsy gave the most accurate estimate of cancer severity before surgery.\u003c\/p\u003e\n\u003ch3\u003eDo these findings apply to men with no visible lesion on prostate MRI?\u003c\/h3\u003e\n\u003cp\u003eNo. This study included only men with MRI-visible lesions (2,103 men). Men with no visible lesions were excluded from the analysis. If your MRI shows no suspicious area, you cannot assume the same benefits. Ask your doctor how these results might apply to your specific situation.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my doctor about prostate biopsy?\u003c\/h3\u003e\n\u003cp\u003eAsk whether a multiparametric prostate MRI can be done before biopsy to look for visible lesions, and whether both MRI-targeted and systematic biopsy can be performed together in the same session. Also ask about the experience of the radiologists and urologists with MRI-fusion biopsy, since imaging expertise affects accuracy.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article:\u003c\/strong\u003e \"MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis\"\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e M. Ahdoot, A.R. Wilbur, S.E. Reese, A.H. Lebastchi, S. Mehralivand, P.T. Gomella, J. Bloom, S. Gurram, M. Siddiqui, P. Pinsky, H. Parnes, W.M. Linehan, M. Merino, P.L. Choyke, J.H. Shih, B. Turkbey, B.J. Wood, and P.A. Pinto\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e The New England Journal of Medicine, Volume 382, pages 917–928, published March 5, 2020. DOI: 10.1056\/NEJMoa1910038\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e The study was funded by the National Institutes of Health (NIH) and others. The electromagnetic tracking device used in the study was developed under a cooperative research-and-development agreement between the NIH and Philips, and is commercially available as the UroNav platform.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStudy Registration:\u003c\/strong\u003e Trio Study, ClinicalTrials.gov number NCT00102544\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research published in The New England Journal of Medicine. It is intended to help patients understand the study's findings and does not constitute medical advice. Patients should discuss their individual diagnostic and treatment options with their healthcare providers.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003c\/main\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47432361312412,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.cn\/products\/combining-mri-targeted-and-standard-biopsy-methods-improves-prostate-cancer-diagnosis-what-2-103-men-can-teach-us","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}